ClinicalTrials.gg
Status unknownNCT02785523Updated May 30, 2016

Clinical Trial on Ganoderma Spore Lipids Combined With Chemo in Patients With G.I. Cancers

A Phase 3 interventional study of Ganoderma Spore Lipids and Placebo in Gastrointestinal Neoplasms, sponsored by Xiaonan Cui. Status unknown at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-05-30.

Sponsored by Xiaonan Cui · Phase 3, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified May 2016), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 110 studies in Gastrointestinal Neoplasms with a site in China — 44 open to participants now, 51 under way, 6 of them phase 3. Gastrointestinal Neoplasms · China.

Planned enrollment
63rd of 88
60 · median 120
Started
2016
with 4 others
Phase 3
11 of 110
5 open now
Registered
14th of 110
by date
Lead sponsor
3 of 110
Xiaonan Cui

Among the 110 studies in Gastrointestinal Neoplasms with a site in China, this one is the 63rd largest by planned enrollment of the 88 interventional ones that give a count, is one of 5 that started in 2016, is one of 11 in phase 3, and was the 14th registered.

Gastrointestinal Neoplasms

698 studies on the registry are indexed under Gastrointestinal Neoplasms; 211 are open to participants now.

Browse Gastrointestinal Neoplasms studies →

Open to participants now

44 of the 110 studies in Gastrointestinal Neoplasms with a site in China are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 160 Gastrointestinal Neoplasms studies recruiting now, 121 (76%) set no upper age limit and 19 (12%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies in Gastrointestinal Neoplasms with a site in China, or all of them as a file.
02

Study summary

A phase III double-blind randomized clinical trial on the effects of ganoderma spore lipids to the immunological response in patients with G.I. Cancers. The trial is randomized, double-blind. Cancer patients are diagnosed based on pathology or cell biology. Patients are randomized into 2 groups: both groups receive chemotherapy. Either group receives ganoderma spore lipids or placebo capsules 600mg three times a day (TID) in addition to the chemotherapy. Clinical evaluation includes chemotherapy drug toxicities, life quality improvement. Blood biochemistry tests mainly include malondialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), adrenaline, nor-adrenaline, tumor necrosis factor (TNF)-α, interleukin (IL)-1b, interleukin (IL)-6, cell flow cytometry on Th1, Th2, Th17, Treg cytokines, as well as serum cortisol, estradiol (female), progesterone (female), testosterone (male), etc.

03

Conditions studied

  • Gastrointestinal Neoplasms
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18-80, male and female.
  • Diagnosis: imaging, cell and pathology report.
  • (ECOG) O-2, more than 3 months.
  • Chemotherapy is not .
  • No apparent surgical trauma during the previous 2 weeks.
  • Past treatment:

    • Biological treatment: at least 4 weeks after previous treatment with immunotherapy or other biological; chemotherapy, at least 6 months after last treatment with chemotherapy and or target therapy.
    • Surgery: had not received transplantation surgery, at least 2 weeks after last major surgery.

Exclusion criteria

Exclusion Criteria:

  • A purulent and chronic infection of wound healing delayed.
  • Diseases of the blood system.
  • Abnormal blood coagulation function.
  • Severe brain disease or primary brain tumors without control, and mentally ill person.
  • Patients with .
  • Pregnant or lactating women.
  • Patients (male/female) with fertility, But the patients themselves or their spouses do not take effective .
  • Allergic constitution.
  • In addition, patients taking part in other clinical trials, being treated with other biotherapy or immunotherapy and researchers consider not suitable for clinical subjects for other reasons will be excluded.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    G. SPORE LIPIDS

    Form: Capsule Dosage and frequency: This group receives ganoderma spore lipids capsules 600mg TID in addition to the chemotherapy. Duration: 6 chemotherapy cycles.

    Drug: Ganoderma Spore Lipids · Drug: Chemotherapy

  • Placebo comparator
    Placebo

    Form: Capsule Dosage and frequency: This group receives placebo capsules 600mg TID in addition to the chemotherapy. Duration: 6 chemotherapy cycles.

    Drug: Placebo · Drug: Chemotherapy

Interventions

  • DrugGanoderma Spore Lipids

    Also known as: G. SPORE LIPIDS

  • DrugPlacebo
  • DrugChemotherapy
06

What researchers measure

Primary outcomes

  1. Adverse Events: neutropenia, leukopenia, thrombocytopenia, anemia, nausea, vomit, fatigue, loss of appetite.

    Time frame: Cycle 2, cycle 4, cycle 6(each cycle is 21 days).

  2. Assessing the quality of life(QOL) in 5 grades and recording: appetite, mental state, sleep, fatigue, pain, attitude towards treatment, daily life ability, treatment of severity of side effects.

    Time frame: Cycle 2, cycle 4, cycle 6(each cycle is 21 days).

Secondary outcomes

  1. Th1/Th2, Th17/Treg in blood.

    Time frame: Cycle 2, cycle 4, cycle 6(each cycle is 21 days).

  2. Interleukin(IL)-1b, interleukin(IL)-6, tumor necrosis factor(TNF)-α in blood.

    Time frame: Cycle 2, cycle 4, cycle 6(each cycle is 21 days).

  3. Estradiol (female), progesterone (female), testosterone (male) in blood.

    Time frame: Cycle 2, cycle 4, cycle 6(each cycle is 21 days).

  4. Vanillylmandelic acid (VMA) in urine.

    Time frame: Cycle 2, cycle 4, cycle 6(each cycle is 21 days).

07

Study locations

1 of 1 sites recruiting
  • The First Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning 116000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2016 and a primary completion of May 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2016
First posted
May 30, 2016
Start
May 2016
Primary completionEst.
May 2017
Last update
May 30, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02785523
Lead sponsor
Xiaonan Cui
Responsible party
Xiaonan Cui (Professor, Chief Physician, The First Affiliated Hospital of Dalian Medical University) — Sponsor-investigator
First posted
May 30, 2016
Start date
May 2016
Primary completion
May 2017 (estimated)
Last update
May 30, 2016

Study contacts

Xiaonan Cui, MD, PhD
Contact
cxn23@sina.com
+8618098876725
Xiaonan Cui, MD, PhD
principal investigator · The First Affiliated Hospital of Dalian Medical University
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion